Clinical Recommendations: Obesity in Children

Objectives

This 2021 Russian clinical guideline, developed for obesity and related conditions, provides an evidence-based framework for diagnosis, treatment, rehabilitation, prevention and organisation of medical care for children and adolescents with excess body weight and obesity, including constitutional-exogenous, endocrine, monogenic and syndromic forms.[1][2][3]Its overarching clinical aim is to prevent and manage obesity-associated complications while supporting normal physical and somatic development, sustainable weight management, self-monitoring and healthier lifestyles.[4]

• Define obesity and excess body weight using body mass index standard deviation scores in people aged 0–19 years, applying World Health Organization growth standards for children aged 0–5 years and reference data for those aged 5–19 years.[5]
• Identify clinical, genetic and syndromic causes of obesity, particularly where obesity has early onset, progresses rapidly, is severe, or is accompanied by developmental delay, neurological signs, dysmorphic features or a relevant family history.[6][7][8]
• Detect obesity-related complications, including arterial hypertension, dyslipidaemia, non-alcoholic fatty liver disease, abnormal glucose regulation, type 2 diabetes, obstructive sleep apnoea and psychosocial concerns.[9][10][11][12]
• Prioritise lifestyle modification through balanced nutrition, regular physical activity, reduced sedentary behaviour, adequate sleep and family-supported behavioural change as the foundation of treatment.[4][13][14]
• Escalate care selectively to pharmacotherapy, somatropin for eligible children with Prader-Willi syndrome, or bariatric surgery for adolescents with severe obesity and defined clinical eligibility.[15][16][17]
• Support population prevention through active identification of excess body weight, particularly in children aged 2–9 years, and through counselling for children and parents on nutrition and physical activity.[18][19]

Implementation

Care is delivered through structured paediatric and paediatric endocrinology assessment, risk stratification, lifestyle-based treatment and clinically indicated specialist referral. The guideline was developed by the Russian Association of Endocrinologists and approved by the Scientific Council of the Ministry of Health of the Russian Federation; its intended users include paediatric endocrinologists, nutrition specialists and general practitioners.[1][20]

• Assess history and examination findings, including obesity onset and trajectory, birth and developmental history, family history, height, weight, body mass index standard deviation score, waist circumference, blood pressure, fat distribution, pubertal development and skin signs such as striae and acanthosis nigricans.[21][22]
• Undertake targeted investigations for lipid abnormalities, liver involvement, glucose dysregulation, diabetes, sleep apnoea and dietary risks. Use broader endocrine, neuroimaging, cytogenetic and molecular genetic testing only when clinical findings indicate endocrine, hypothalamic, monogenic or syndromic obesity.[10][11][12][23]
• Provide an age-appropriate balanced diet with adequate protein, vegetables, fruit, vitamins and micronutrients, while limiting added sugars, sugary drinks, sweet dairy products and excessive portions. Restrictive, unbalanced, ketogenic and very low-carbohydrate diets are not presented as routine approaches.[13][24]
• Promote at least 60 minutes of daily moderate- to vigorous-intensity physical activity for children and adolescents aged 6–17 years, including high-intensity activity at least three times weekly, and reduce passive screen time.[24][25][14]
• Use pharmacotherapy from age 12 when a healthy-lifestyle intervention has been ineffective for at least one year. Liraglutide may supplement diet and activity; orlistat may be considered for those aged over 12, while metformin is not routinely recommended solely for obesity without underlying disease or comorbidity.[15][26][27]
• Consider bariatric surgery in specialised centres for adolescents with body mass index above 35 kg/m² and severe complications, or above 40 kg/m² irrespective of complications, after documented failure of 12 months of conservative treatment and with capacity for long-term multidisciplinary follow-up.[17][28][29]
• Organise follow-up through paediatricians and paediatric endocrinologists, initially monthly for three months for children with obesity and subsequently at clinically indicated intervals; use planned inpatient care where comprehensive complication screening, complex treatment, monitoring or surgery cannot be delivered as an outpatient service.[18][30]
• Monitor treatment using body mass index standard deviation score, anthropometric measures, waist circumference, blood pressure, dietary intake and relevant metabolic or complication-specific measures. After bariatric surgery, monitor vitamin and micronutrient status and correct deficiencies promptly.[4][31][32][33]
• Support implementation with clinical algorithms, patient information, standards for primary and specialised obesity care, medicinal-product information and guidance on indications, contraindications and administration.[3][34]
• Maintain guideline quality through literature review, evidence grading, expert consensus, external review and periodic updates at least every three years or when material new evidence emerges.[35][36][37][34]

Monitoring & Evaluation

The guideline’s evaluation approach is primarily clinical and quality-assurance based. It specifies repeated assessment of anthropometric status, obesity-related comorbidities, treatment response and follow-up needs, while providing evidence and recommendation grades for many actions. It does not establish a unified national performance framework, routine reporting system, surveillance database, audit timetable or institutional accountability mechanism.[3][19][37][38]

• Monitor body mass index standard deviation score (BMI SDS) during lifestyle treatment, initially over 6–12 months, and assess longer-term reduction in BMI SDS, excess-weight reduction or attainment of normal weight, physical and somatic development, self-monitoring capacity, motivation and prevention of comorbidities.[4]
• Measure height, weight, BMI SDS, waist circumference, adipose-tissue distribution and arterial blood pressure in children with obesity or excess weight; interpret blood pressure by age, sex and height, and use 24-hour ambulatory monitoring when hypertension is suspected.[21]
• Classify paediatric hypertension using the average of three systolic and/or diastolic measurements, assigning the higher category where the two values differ.[9][22]
• Assess clinical signs associated with obesity-related disease, including skin striae, follicular keratosis, acanthosis nigricans, androgen excess and pubertal development using Tanner staging.[22]
• Screen for metabolic and organ complications through lipid testing, liver enzyme measurement, liver ultrasonography, glucose assessment and oral glucose tolerance testing where indicated.[10][11][39][40]
• Use food diaries and 24-hour dietary recall to assess dietary intake and changes in nutritional status, including the effectiveness of dietetic and pharmacological treatment.[41][23]
• Undertake targeted investigations for syndromic, endocrine or monogenic obesity when clinically suspected rather than routinely conducting extensive hormonal, neuroimaging, molecular-genetic or cytogenetic testing.[23][42][43]
• Monitor insulin resistance only where strict clinical indications exist; the Matsuda index derived from oral glucose tolerance testing is identified as a practical measure, with a value below 2.6 indicating insulin resistance.[44][45]
• Use body-composition analysis and, in specialised settings, indirect respiratory calorimetry where clinically appropriate to support personalised dietary and therapeutic planning; neither is mandatory for routine care.[46][47][48]
• Monitor treatment-specific outcomes and safety. For liraglutide, cited trial outcomes include body-weight and BMI SDS change; for orlistat, the evidence base includes weight-change findings and common gastrointestinal adverse effects.[49][26]
• Monitor children receiving somatropin for Prader-Willi syndrome through anthropometry, adrenocortical function, bone age, insulin-like growth factor 1, glucose, insulin and glycated haemoglobin, and use polysomnography before and during therapy, especially in the first three to six months.[50]
• Require evidence that conservative treatment has been ineffective for 12 months in specialised centres before considering bariatric surgery, and ensure long-term postoperative follow-up.[17]Postoperative monitoring includes vitamin and micronutrient status, particularly calcium, vitamin D, iron, folate and vitamin B12.[32]
• Provide paediatric and paediatric-endocrinology follow-up for children with obesity, including monthly visits during the first three months and subsequently clinically indicated visits; monitor anthropometry, BMI, waist circumference, physical development, lifestyle and complications.[33][18]
• Apply 12 stated quality-of-care criteria covering clinical examination, screening for syndromic or monogenic obesity, metabolic and imaging investigations, dietary assessment and counselling on nutrition and physical activity. Most are graded C with evidence level 5, while selected assessments and counselling are designated Good Practice Points.[19]
• Use evidence appraisal, external expert review, consultation with frontline clinicians and working-group quality control in guideline development. Recommendation strength is classified as A, B or C, and evidence frameworks distinguish diagnostic evidence from prevention, treatment and rehabilitation evidence.[35][36][37][20][38]
• Update the clinical recommendations at least every three years and when relevant new evidence emerges, considering proposals from professional organisations and comprehensive assessments of medicines, medical devices and clinical approval results.[34]
• Use the World Health Organization Childhood Obesity Surveillance Initiative as an international comparative surveillance mechanism for trends in school-age excess weight and obesity; the cited initiative covered more than 300,000 children in 38 European countries.[51]

Evidence grades are stated for numerous individual recommendations, but these grades do not constitute programme indicators. Beyond clinical follow-up, quality criteria, evidence review and the cited international surveillance initiative, the source does not specify indicator definitions, reporting frequencies, data flows, audit arrangements, outcome targets or named bodies responsible for accountability.[3][19][34]

Costing & Financing

No explicit costing, budget, funding allocation, financing source, resource-mobilisation plan, funding gap or economic assumption is specified. No pharmacoeconomic analysis or cost analysis was undertaken.[36]

• Recognise resource implications described qualitatively for selected services: the hyperinsulinaemic-euglycaemic clamp is invasive and expensive, requires specially trained staff and complex statistical processing, and is not presented as a routine assessment method.[45]
• Provide specialised-centre capacity where indirect respiratory calorimetry is used, as the method may require additional clinician training.[47][48]
• Ensure multidisciplinary expertise and trained clinicians for adolescent bariatric surgery, recognising the potential need for repeat procedures, hospital readmission and prolonged postoperative monitoring.[52][53][32]
• Note that the guideline gives no medicine prices or reimbursement arrangements for liraglutide, orlistat, metformin or somatropin, despite describing their clinical use in defined circumstances.[14][15][26][16][54]

Accordingly, the source supports no calculation of programme costs, treatment costs, affordability, cost-effectiveness, budget impact, unmet financing needs or funding requirements.[36]